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INFLUENZA VACCINATION IN SCHOOL-AGED CHILDREN
By: Isabella Jao, NS., Chloe McFadin, NS., Nica Nuguid, NS., 
Dan Recinto, NS., Kaitlin VanRyn, NS.
Implications for PracticeIntroduction 
Findings
Should schools in the United States require children between the 
ages of six months to 17 years to have flu vaccination shots? 
Influenza is a serious disease that can lead to hospitalization and 
sometimes even death. According to the Center of Disease Control 
(CDC), every flu season varies, and an influenza infection can affect 
people differently. Millions of people get the flu every year, hundreds 
of thousands of people are hospitalized, and thousands or tens of 
thousands of people die from flu-related causes every year. Everyone 
is at risk for influenza, but the highest risk lies within children who are 
still developing their immune systems. However, with vaccines, this 
risk is easily preventable and can decrease a person’s chances of 
acquiring the infection. As such, the CDC recommends that every 
person six months and older should be vaccinated annually. This is 
even more important for children because they attend schools where 
they have maximum exposure to various strains of influenza six to ten 
hours daily. They can easily spread and contract the disease in their 
school environment, specifically from children that are not vaccinated. 
This leads to the hypothesis that children six months to 17 years 
should be required to receive influenza vaccinations.
Study Design/Sample 
● Assess parental understanding of implications and 
reasons for vaccination.
● Educate on the importance of receiving the 
influenza vaccine annually. 
● Inform the parent and patient of the adverse affects 
of the vaccination.
● Explain to parent and patient other methods of 
influenza prevention.
Conclusion/Further Study
Influenza Vaccination in Pediatric Population
• Many parents feel more compelled to get their child vaccinated when their health care provider 
verbally explores the topic with them
• Of the 119 parents who received the influenza vaccine stated that they would continue to 
vaccinate their child against influenza. Only 5% said they would not vaccinate their child 
• Many parents and patients get the vaccine when it is convenient and low in cost. 
• It is more cost effective when the child is between 6-23 months old, and with high risk patients with 
chronic illnesses to reduce hospital visits. 
• Children have a higher rate of clinical visits and emergency department encounters during the flu 
season. 
• The major drivers of vaccination were prevention of influenza (95.1%), a doctors recommendation 
(89.5%), and the desire to reduce influenza symptoms (83.3%). 
• The average cost of a flu vaccine is $20 per person. 
Conclusion
● There is not enough information gathered to support 
the hypothesis that children at the ages of 6 months to 
17 years be required for vaccinations of influenza. 
● Need the perspective of experts for these kinds of 
research to help better outweigh the different 
variables. 
● While studies show that there are health benefits to 
support the hypothesis, it does not prove to be cost 
effective as age increases.
● The cost may outweigh the benefits for those of lower 
socioeconomic class and those with low risk for 
contracting the influenza.
● It is however both cost effective and health beneficial 
for children ages 6 to 23 months where they have 
weaker immune systems.
● Instead of original hypothesis, Requiring healthcare 
providers to inform and clear up misconceptions about 
the influenza vaccine to decrease the prevalence the 
spread of the flu may be a future study to look at.
Further Studies
● Expert viewpoints of influenza vaccinations and 
thoughts in how to society can better prevent the 
prevalence of the flu.
● More qualitative studies on viewpoints of influenza 
vaccination and the reason for their beliefs in taking 
influenza vaccination
● Further quantitative and qualitative studies on herd 
immunity. 
● Further qualitative studies on social media and the 
effects in vaccination rates.
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Study Title Design Sample/ Demographics 
The efficacy of live attenuated, cold-
adapted, trivalent, intranasal 
influenza virus vaccine in children
Quantitative Study
Prospective, randomized,
double blind, placebo 
controlled, and 
multicenter
n= 288
Children 15-17 months
Location: Mountain View, 
California
Date: 1996-1997
Parents’ decision-making regarding 
vaccinating their children against 
influenza: A web-based survey
Qualitative web-based
survey
n= 500
Parents of children between 2-12 
y/o
Location: United States
Date: 2010
Health benefits, risk, and cost-
effectiveness of influenza vaccination 
of children
Quantitative Study n=5000
(1000 children per subgroup
Children 6 months – 17y/o
Location: Massachusetts and
Georgia, United States)
Date: 2004-2004 Influenza 
seasons
The under recognized burden of 
influenza in young children
Quantitative Study n= 2797
Children < 5 y/o
Location: three US counties
Date: October 2000 to September 
2004
Parental Perspectives on influenza 
vaccination of children with chronic 
medical conditions
Mixed Study n=183
Parents of 2-13 y/o children with 
high-risk medical conditions from 
low-income neighborhoods
Location: United States
Date: 2003 - 2006
Influenza vaccine efficacy in young 
children attending childcare: A 
randomized controlled trial
Mixed Study
Double-blind, 
randomized controlled 
trial
n=124
Children b/w 6 to <48 months
Location: Sydney, Australia
Date: 2011
Influenza 
Vaccine at
Brand/Trade Name NDC Packaging CDC Cost/Dose Private Sector 
Cost/Dose 
Contract 
End Date
Manufacturer Contract #
> 6 mo FluzoneⓇ
Quadrivalent
49281 – 0627-15 10 dose vial $ 14.52 $ 16.622 2/28/2018 Sanofi 
Pasteur
200-2017-
92736
6 – 36 mo FluzoneⓇ
Quadrivalent
Pediatric dose
49281 – 0517-25 10 pack – 1 dose 
syringe
$ 15.675 $ 18.72 2/28/2018 Sanofi 
Pasteur
200-2017-
92736
> 36 mo FluzoneⓇ
Quadrivalent
49281 – 0417-50 10 pack – 1 dose 
syringe
$15.675 $ 17.97 2/28/2018 Sanofi 
Pasteur
200-2017-
92736
49281 – 0417-10 10 pack – 1 dose 
vial
$15.675 $17.97
> 36 mo FluarixⓇ
Quadrivalent
58160 – 0907-52 10 pack – 1 dose 
syringe
$14.43 $16.82 2/28/2018 GlaxoSmithKli
ne
200-2017-
92735
> 6 mo FluLaval 
Quadrivalent
19515 – 0896-11 10 dose vial $13.55 $15.77 2/28/2018 GlaxoSmithKli
ne
200-2017-
92735
19515 – 0912-52 10 pack – 1 dose 
syringe
$14.43 $16.82
> 4 years FlucelavaxⓇ
Quadrivalent
70461 – 0201-01 10 pack – 1 dose 
syringe
$15.42 $21.22 2/28/2018 GlaxoSmithKli
ne
200-2017-
92735
70461 – 0301-10 10 dose vial $14.07 $20.12
Pediatric Influenza Vaccine Price List
The table below reflects the 2017-2018 influenza vaccine price list
